CIN
MCID: CRV045
MIFTS: 39

Cervical Intraepithelial Neoplasia (CIN)

Categories: Rare diseases

Aliases & Classifications for Cervical Intraepithelial Neoplasia

MalaCards integrated aliases for Cervical Intraepithelial Neoplasia:

Name: Cervical Intraepithelial Neoplasia 52 54 71
Cin 47

Classifications:



External Ids:

UMLS 71 C0206708

Summaries for Cervical Intraepithelial Neoplasia

MalaCards based summary : Cervical Intraepithelial Neoplasia, also known as cin, is related to cervix uteri carcinoma in situ and suppressor of tumorigenicity 3. An important gene associated with Cervical Intraepithelial Neoplasia is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Keratinization and Pathways in cancer. The drugs Aluminum hydroxide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include testes, cervix and t cells.

Wikipedia : 74 Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is the abnormal growth of... more...

Related Diseases for Cervical Intraepithelial Neoplasia

Diseases related to Cervical Intraepithelial Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 258)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 33.8 KRT17 FHIT CDKN2A
2 suppressor of tumorigenicity 3 32.0 FHIT CDKN2A
3 in situ carcinoma 31.5 KRT8 KRT17 CDKN2A
4 chronic cervicitis 31.3 KRT17 CDKN2A
5 vulvar intraepithelial neoplasia 31.2 CDKN2A BIRC5
6 papilloma 31.0 KRT8 IVL CDKN2A
7 cervical squamous cell carcinoma 30.9 MKI67 KRT8 KRT17 CDKN2A
8 bowenoid papulosis 30.6 TERT CDKN2A
9 leukoplakia 30.4 MKI67 KRT8
10 skin melanoma 30.0 NME1 MKI67 CDKN2A
11 squamous cell carcinoma 29.5 VEGFC NME1 MKI67 IVL FHIT CDKN2A
12 cervical cancer 29.0 VEGFC TERT TERC NME1 MTHFR KRT17
13 endometrial cancer 28.7 VEGFC TERT TERC NME1 MKI67 CDKN2A
14 renal cell carcinoma, nonpapillary 28.6 VEGFC NME1 MKI67 KRT8 FHIT BIRC5
15 basal cell carcinoma 28.5 TERT MKI67 KRT8 KRT17 IVL CDKN2A
16 breast cancer 26.7 VEGFC TERT NME1 MTHFR MKI67 KRT8
17 squamous cell papilloma 11.0
18 cervicitis 10.8
19 chlamydia 10.7
20 adenocarcinoma in situ 10.7
21 anogenital venereal wart 10.7
22 adenocarcinoma 10.6
23 immune deficiency disease 10.6
24 bacterial vaginosis 10.6
25 vaginal discharge 10.6
26 retinoblastoma 10.5
27 familial retinoblastoma 10.5
28 spitz nevus 10.4 MKI67 CDKN2A
29 ameloblastic carcinoma 10.4 MKI67 CDKN2A
30 vaginal cancer 10.4
31 cervix carcinoma 10.4
32 cecal benign neoplasm 10.4 TERT CDKN2A
33 cecum adenoma 10.4 TERT CDKN2A
34 oral leukoplakia 10.4 MKI67 CDKN2A
35 pulmonary fibrosis, familial 10.4 TERT TERC
36 inherited bone marrow failure syndromes 10.4 TERT TERC
37 vaginitis 10.4
38 herpes simplex 10.4
39 malignant peritoneal mesothelioma 10.4 CDKN2A BIRC5
40 adenosquamous carcinoma 10.3
41 placenta disease 10.3
42 47,xyy 10.3
43 cytokine deficiency 10.3
44 spitzoid melanoma 10.3 TERT CDKN2A
45 dyskeratosis congenita autosomal dominant 10.3 TERT TERC
46 dyskeratosis congenita, autosomal dominant 1 10.3 TERT TERC
47 adult malignant schwannoma 10.3 CDKN2A BIRC5
48 cryptogenic cirrhosis 10.3 MTHFR KRT8
49 anus cancer 10.3
50 cervical adenocarcinoma 10.3

Graphical network of the top 20 diseases related to Cervical Intraepithelial Neoplasia:



Diseases related to Cervical Intraepithelial Neoplasia

Symptoms & Phenotypes for Cervical Intraepithelial Neoplasia

Drugs & Therapeutics for Cervical Intraepithelial Neoplasia

Drugs for Cervical Intraepithelial Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Racepinephrine Approved Phase 4 329-65-7 838
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5 Monophosphoryl lipid A Phase 4
6 Anesthetics, Local Phase 4
7 Adrenergic beta-Agonists Phase 4
8 Adrenergic alpha-Agonists Phase 4
9 Respiratory System Agents Phase 4
10 Adrenergic Agents Phase 4
11 Epinephryl borate Phase 4
12 Vasoconstrictor Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Mydriatics Phase 4
15 Bronchodilator Agents Phase 4
16 Adrenergic Agonists Phase 4
17 Sympathomimetics Phase 4
18 Neurotransmitter Agents Phase 4
19
leucovorin Approved Phase 3 58-05-9 6006 143
20
Aluminum sulfate Approved Phase 3 10043-01-3
21
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
22
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
23
Pancrelipase Approved, Investigational Phase 3 53608-75-6
24
Eugenol Approved Phase 3 97-53-0 3314
25
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Fenretinide Investigational Phase 3 65646-68-6
28
3,3'-diindolylmethane Investigational Phase 3 1968-05-4
29 Immunologic Factors Phase 3
30 Vitamin B Complex Phase 3
31 Folate Phase 3
32 Vitamin B9 Phase 3
33 Retinamide Phase 3
34 Dermatologic Agents Phase 3
35 Immunoglobulins Phase 3
36 Antibodies Phase 3
37 Hemostatics Phase 3
38 Pharmaceutical Solutions Phase 3
39 Antiviral Agents Phase 3
40 Keratolytic Agents Phase 3
41 Sodium Channel Blockers Phase 3
42 Anti-Arrhythmia Agents Phase 3
43 Diuretics, Potassium Sparing Phase 3
44 Liver Extracts Phase 3
45 pancreatin Phase 3
46 Olive Phase 3
47 Anesthetics Phase 3
48 Adjuvants, Immunologic Phase 3
49 interferons Phase 3
50
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556

Interventional clinical trials:

(show top 50) (show all 315)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer Unknown status NCT02629510 Phase 4 Tachosil
2 Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia? Unknown status NCT00842738 Phase 4
3 HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico Unknown status NCT03105856 Phase 4
4 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
5 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
6 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Completed NCT03629886 Phase 4
7 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
8 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
9 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
10 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
11 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Active, not recruiting NCT03180034 Phase 4
12 Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial Enrolling by invitation NCT02149030 Phase 4
13 Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation Unknown status NCT01095198 Phase 2, Phase 3
14 The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Unknown status NCT03366493 Phase 3
15 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
16 A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 Completed NCT00003075 Phase 3 Fenretinide
17 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
18 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
19 Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693 Completed NCT00929526 Phase 3
20 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
21 Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN) Completed NCT00212381 Phase 3 di indolylmethane (DIM)
22 Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study Completed NCT03355820 Phase 3
23 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
24 An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] Completed NCT00462813 Phase 3 oral microencapsulated diindolylmethane
25 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3 Fluorouracil
26 A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 Completed NCT00316706 Phase 3
27 Single Visit Cervical Cancer Prevention Program Completed NCT00237562 Phase 3
28 Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial Completed NCT01505920 Phase 3
29 Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
30 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
31 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
32 A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ. Completed NCT00995020 Phase 3
33 Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Completed NCT02330471 Phase 3
34 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
35 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
36 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
37 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
38 Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens Completed NCT00973362 Phase 3
39 A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Completed NCT00001073 Phase 3 Isotretinoin
40 Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women? Completed NCT01014026 Phase 3
41 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
42 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients. Completed NCT00677677 Phase 3
43 Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo Completed NCT02346227 Phase 3 AV2;Placebo
44 Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL Recruiting NCT03721978 Phase 3
45 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix Active, not recruiting NCT03185013 Phase 3
46 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
47 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Active, not recruiting NCT02733068 Phase 3
48 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Active, not recruiting NCT03998254 Phase 3 V503;Gardasil
49 A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer. Not yet recruiting NCT03848039 Phase 3 Placebo
50 ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial Terminated NCT01283763 Phase 3 Topical Imiquimod

Search NIH Clinical Center for Cervical Intraepithelial Neoplasia

Genetic Tests for Cervical Intraepithelial Neoplasia

Anatomical Context for Cervical Intraepithelial Neoplasia

MalaCards organs/tissues related to Cervical Intraepithelial Neoplasia:

40
Testes, Cervix, T Cells, Endothelial, Breast, Lymph Node, Skin

Publications for Cervical Intraepithelial Neoplasia

Articles related to Cervical Intraepithelial Neoplasia:

(show top 50) (show all 7731)
# Title Authors PMID Year
1
The presence of methylation of the p16INK4A gene and human papillomavirus in high-grade cervical squamous intraepithelial lesions. 61 54
20186007 2010
2
Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. 54 61
20069634 2010
3
Protein p 16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix. 61 54
20090213 2010
4
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression. 54 61
19937343 2010
5
The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. 61 54
19760026 2010
6
[Amplification and clinical significance of hTERC gene in the cervical exfoliated cells from natural population in Shenzhen]. 61 54
20193234 2009
7
p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal. 54 61
19372590 2009
8
Cervical intraepithelial neoplasia and aneusomy of TERC: assessment of liquid-based cytological preparations. 61 54
19191295 2009
9
Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. 61 54
19476635 2009
10
Ancillary testing of liquid-based cytology specimens for identification of patients at high risk of cervical cancer. 54 61
18936966 2008
11
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 54 61
18958930 2008
12
Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. 61 54
19471565 2008
13
Expression of p16 and cervical infection with high-risk human papillomavirus are not related to p53 activity in cervical intraepithelial neoplasia. 54 61
18021213 2008
14
p16INK4 expression in precursor lesions of squamous cell cervical cancer related to the presence of HPV-DNA. 54 61
18719739 2008
15
[Expression of MIF, VEGF and p16 proteins and their correlation with clinicopathological features in cervical cancer]. 61 54
19062717 2008
16
The utility of p16(Ink4a) in discriminating between cervical intraepithelial neoplasia 1 and nonneoplastic equivocal lesions of the cervix. 61 54
18466028 2008
17
[Correlations of high-risk human papillomaviral load to cervical intraepithelial neoplasia grades, expression of Ki-67 and P6ink4a and follow-up]. 54 61
18479603 2008
18
Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. 61 54
18561741 2008
19
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling. 54 61
18317213 2008
20
Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. 61 54
18191996 2008
21
CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia. 61 54
18315605 2008
22
Senescence and apoptosis in carcinogenesis of cervical squamous carcinoma. 61 54
17632454 2007
23
p16INK4a expression in invasive vulvar squamous cell carcinoma. 54 61
17721272 2007
24
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 54 61
17638654 2007
25
Telomerase and markers of cellular proliferation are associated with the progression of cervical intraepithelial neoplasia lesions. 54 61
17581401 2007
26
The association of p16(INK4A) and fragile histidine triad gene expression and cervical lesions. 54 61
17596760 2007
27
The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. 61 54
17581402 2007
28
Concurrent high expression of human telomerase reverse transcriptase and human nonmetastatic clone 23 in high-grade squamous intraepithelial neoplasia and squamous cell carcinoma of uterine cervix. 54 61
17359290 2007
29
Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. 61 54
17549406 2007
30
The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. 54 61
17433827 2007
31
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 61 54
17294450 2007
32
[Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue]. 54 61
17697601 2007
33
The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. 61 54
17504380 2007
34
CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). 54 61
17394499 2007
35
Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results. 54 61
17334990 2007
36
Immunohistochemical expression of p16(INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and low-grade squamous intraepithelial lesions. 61 54
17415114 2007
37
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 54 61
17545048 2007
38
Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. 54 61
17303386 2007
39
The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance. 61 54
17046054 2007
40
The role of p53, Bcl-2 and Ki-67 in premalignant cervical lesions and cervical cancer. 61 54
17713095 2007
41
A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. 61 54
17078096 2006
42
Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer. 61 54
16537673 2006
43
Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis. 54 61
17009984 2006
44
Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, cyclin A in predicting cervical intraepithelial neoplasia, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union. 61 54
16835319 2006
45
p14ARF and p16INK4A, two products of the same gene, are differently expressed in cervical intraepithelial neoplasia. 61 54
16406113 2006
46
Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. 61 54
16778587 2006
47
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 61 54
16845792 2006
48
p16 expression in the female genital tract and its value in diagnosis. 54 61
16462152 2006
49
Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. 54 61
16394279 2006
50
Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. 54 61
16112431 2005

Variations for Cervical Intraepithelial Neoplasia

Expression for Cervical Intraepithelial Neoplasia

Search GEO for disease gene expression data for Cervical Intraepithelial Neoplasia.

Pathways for Cervical Intraepithelial Neoplasia

Pathways related to Cervical Intraepithelial Neoplasia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 SPRR1B KRT8 KRT17 IVL
2 11.75 VEGFC TERT TERC CDKN2A BIRC5
3 11.04 TERT NME1 BIRC5

GO Terms for Cervical Intraepithelial Neoplasia

Cellular components related to Cervical Intraepithelial Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10 TERT TERC SPRR1B NME1 KRT8 KRT17
2 cytosol GO:0005829 9.7 TERT SPRR1B NME1 MTHFR KRT8 KRT17
3 telomerase holoenzyme complex GO:0005697 9.16 TERT TERC
4 telomerase catalytic core complex GO:0000333 8.62 TERT TERC

Biological processes related to Cervical Intraepithelial Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide metabolic process GO:0009117 9.43 NME1 FHIT
2 peptide cross-linking GO:0018149 9.4 SPRR1B IVL
3 negative regulation of cellular senescence GO:2000773 9.37 TERT TERC
4 telomere maintenance via telomerase GO:0007004 9.32 TERT TERC
5 purine nucleotide metabolic process GO:0006163 9.26 NME1 FHIT
6 keratinization GO:0031424 9.26 SPRR1B KRT8 KRT17 IVL
7 replicative senescence GO:0090399 9.16 TERT CDKN2A
8 cornification GO:0070268 8.92 SPRR1B KRT8 KRT17 IVL

Molecular functions related to Cervical Intraepithelial Neoplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA-directed DNA polymerase activity GO:0003964 9.16 TERT TERC
2 telomerase activity GO:0003720 8.96 TERT TERC
3 telomerase RNA reverse transcriptase activity GO:0003721 8.62 TERT TERC

Sources for Cervical Intraepithelial Neoplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....